ArticleAbdominal radiology (New York)2025
Application of the three-phase T1-derived model in staging liver fibrosis in chronic hepatitis: a comparative study with magnetic resonance elastography.
Article in Abdominal radiology (New York), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
objectiveThis study aims to evaluate the accuracy of a three-phase T1-derived model in staging liver fibrosis in patients with chronic hepatitis, in comparison with magnetic resonance elastography (MRE).
methodsA total of 174 patients with chronic hepatitis were enrolled. The acquisition of three-phase longitudinal relaxation times (T1-Unenh = A, T1-DLP = B, T1HBP = C) from magnetic resonance enhancement examinations, as well as magnetic resonance elastography (MRE) and liver biopsy information for patients.Binary logistic regression was employed to construct models ABC. The diagnostic performance of these models was evaluated using the receiver operating characteristic (ROC) curve and DeLong's test. Furthermore, the MRE and ABC models were subjected to a comprehensive analysis through 10-fold cross-validation.
resultsIn all liver fibrosis stages (≥ F1-≥F4), both MRE and the ABC model showed moderate correlation with METAVIR fibrosis staging, with significant differences between groups (all P < 0.05). The area under the curve (AUC) for each group of the ABC model was above 0.84. DeLong's test indicated that in the ≥ F2, ≥F3, and ≥ F4 groups, the ABC model was comparable to MRE (all P > 0.05). Ten-fold cross-validation further confirmed that only in the ≥ F3 group did the ABC model outperform MRE in terms of comprehensive performance.
conclusionThis study successfully validated the effectiveness of the three-phase T1-derived model in staging liver fibrosis in patients with chronic hepatitis. In stages ≥ F2, ≥F3, and ≥ F4, it is comparable to MRE, especially showing superior application value in the ≥ F3 stage.
Indexed as
Identifiers
39939541What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.